Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative A global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society... Read More

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up period Of the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at... Read More

BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topline data readout in the second half of calendar year 2025, with last patient last visit completed in July; Roivant and Priovant... Read More

BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link . The... Read More

Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative... Read More

BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video... Read More

BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. Brepocitinib program progressing well with rapid enrollment in non-infectious uveitis (NIU) Phase 3 study and first patients dosed in cutaneous sarcoidosis (CS) proof-of-concept trial, with readouts... Read More

BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link... Read More

Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. retired from his role as Immunovant CEO and Director Leadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant IND cleared for a potentially registrational program for IMVT-1402 in... Read More

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across... Read More

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief... Read More

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed... Read More

BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in... Read More

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zest Health, the first value-based virtual care company focused on treating patients with inflammatory skin diseases, today announced $13 million in seed funding. Zest Health’s platform provides personalized dermatology care that minimizes unnecessary pharmaceutical utilization while producing sustainable clinical outcomes. The roughly 40 million Americans with eczema and psoriasis... Read More

BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link . The... Read More

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study failed to... Read More

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study failed to... Read More

BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program... Read More

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link . The... Read More

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to... Read More

Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD), which affects ~200,000 patients in the U.S. and Europe; PH-ILD prevalence is meaningfully greater than that of pulmonary arterial hypertension (PAH)... Read More

Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability across the spectrum of pulmonary hypertension (PH) In the Phase 1b ATMOS study, presented today at the European Respiratory Society (ERS) Congress, a single dose of inhaled mosliciguat in PH patients (N=38) led to sustained,... Read More

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs at week 12 Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves’ Disease (GD) Real world claims data indicates... Read More

BASEL, Switzerland and LONDON and NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided a business update. Immunovant completed enrollment in batoclimab pivotal myasthenia gravis (MG) trial; topline results and initiation of a potentially registrational program in MG for IMVT-1402 on track for fiscal year end (March 31,... Read More

BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 8, 2024, to report its financial results for the first quarter ended June 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link . The... Read More

BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure rates observed to date among studies in active non-infectious uveitis (NIU), supporting initiation of a pivotal program in NIU in the... Read More

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link... Read More

Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates... Read More

BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the completion of a near-term milestone Batoclimab produced positive results in Graves’ disease with... Read More

BASEL, Switzerland and LONDON and NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, February 13, 2024, to report its financial results for the third quarter ended December 31, 2023, and provide a business update. To access the conference call by phone, please register online using this registration link . The... Read More

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates. This Phase 2 proof-of-concept trial is an... Read More

BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease,... Read More

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study IMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort data... Read More

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52 Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study Priovant expects to announce topline results... Read More

Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitis IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg... Read More

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivan t (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. “I’m thrilled to be adding Mayukh to our board. Mayukh has been with the... Read More

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update. To access the conference call by phone, please register online using this registration link . The presentation and... Read More

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitis Roche will also obtain an option to enter into a global collaboration with Pfizer on... Read More

BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics , an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry.... Read More

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort IMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26,... Read More

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) that remained outstanding following 5:00 p.m. New York City Time on September 1, 2023 (the... Read More

BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”). The Redemption Fair Market... Read More

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses First patient has been dosed in the TAHOE study, a global Phase 2 trial of RVT-3101 in Crohn’s disease, with topline data from the induction portion expected in the fourth quarter of calendar year 2024 Initial data... Read More

BASEL, Switzerland and LONDON and NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a business update. To access the conference call by phone, please register online using this registration link . The presentation and... Read More

BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to purchase Roivant’s common shares (the “Common Shares”) pursuant to its Warrant Agreement dated September... Read More

The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn’s disease (CD) Roivant recently announced highly favorable results from the TUSCANY-2 Phase 2b study in ulcerative colitis (UC), demonstrating improved efficacy from the induction to maintenance period of treatment with RVT-3101 Telavant plans to initiate a Phase 3... Read More

BASEL, Switzerland, LONDON, and NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. Roivant (Nasdaq: ROIV) came in at no. 25 on the list of 100 Best Workplaces for Innovators and is the winner on the Science and Technology... Read More

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with topline data expected in the fourth quarter of calendar year 2024 VTAMA ® (tapinarof) net product revenue was $13.7M for the quarter and $28.0M... Read More

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with topline data expected in the fourth quarter of calendar year 2024 VTAMA ® (tapinarof) net product revenue was $13.7M for the quarter and $28.0M... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provide business update. To access the conference call by phone, please register online using... Read More

This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission 1 (36% at week 56 vs. 29% at week 14) and Endoscopic Improvement 2 (50% vs. 36%) At the expected Phase 3 once-monthly subcutaneous dose in the biomarker positive population, RVT-3101 treatment resulted in... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 (anti-TL1A antibody) in ulcerative colitis. To access the call by phone, please register online using this... Read More

ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10 th consecutive positive Phase 3 study since 2019 45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-AD™ response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on vehicle... Read More

Clinical trial intelligence platform hits key commercial milestones, expands leadership team NEW YORK / Apr 04, 2023 / Business Wire / Lokavant, the clinical trial intelligence platform company, has achieved significant business milestones within three months of the company’s $21 million Series A funding announcement,... Read More

NEW YORK / Apr 04, 2023 / Business Wire / Lokavant, the clinical trial intelligence platform company, announces strategic new hires to drive its mission to make clinical trials smarter. Lokavant, launched in 2020, has hired Andrew (AJ) Mills as executive vice president of sales; Doug Weatherhead as vice president of marketing; and Meredith Dees , as vice president of product. Each brings decades of industry experience and... Read More

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics , an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. Covant significantly accelerates drug... Read More

46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD TM ) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001) All secondary endpoints were met with a high degree of statistical significance, including 59.1% of subjects treated with VTAMA cream... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis. To access the call by phone, please register online using this registration link . A... Read More

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics , a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in... Read More

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics , an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets. “This is a very exciting time... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant in 2014 with the vision of revolutionizing drug development. Over the past decade, the FDA has granted six FDA approvals for medicines... Read More

$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launch VTAMA payor coverage significantly expanded, with 57% of commercial lives now covered ADORING 1 and 2 trials evaluating tapinarof in atopic dermatitis fully enrolled, with topline data expected from the first study in March 2023 and... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares to be sold in the offering are to be sold by Roivant. The gross proceeds to Roivant from the offering, before deducting the... Read More

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares. All of the common shares are being offered by Roivant. The... Read More

Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ET Roivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at... Read More

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose At the expected Phase 3 dose, among patients who were positive for a biomarker that was prospectively defined in TUSCANY-2, clinical... Read More

Investment will transform the clinical research industry for smarter and faster trials PRINCETON, N.J. and NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Edison Partners , a leading growth equity investment firm, today announced it is leading a $21 million investment round in Lokavant , the leading clinical trial intelligence... Read More

Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase 2b study ( TUSCANY-2 ) with final results expected in 1H 2023 BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Dec. 01, 2022... Read More

Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. EST Roivant will present at investor conferences in November Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a corporate update. To access the conference call by... Read More

Three healthcare investor conferences in September across Boston, New York and London Roivant Investor Day will take place virtually on September 28 th starting at 11 a.m. EDT Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences and hold an investor day in September: Citi BioPharma Conference in Boston on Wednesday, September 7 th H.C. Wainwright Global Investment Conference in New York... Read More

Early launch data for VTAMA ® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical novel chemical entity for plaque psoriasis in 25 years The Journal of the American Academy of Dermatology (JAAD) published the... Read More

Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDT Roivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Monday, August 15, 2022 to report its financial results for... Read More

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical psoriasis prescriptions... Read More

Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and... Read More

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Tuesday, June 28, 2022 to report its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provide a corporate... Read More

EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment (PGA) score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% of patients versus 6% in vehicle in PSOARING 2 achieving clear or almost clear with a minimum 2-grade improvement at week 12 (p<0.0001... Read More

Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global Healthcare Conference in New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline will present. H.C. Wainwright Global Investment Conference in Miami on Tuesday, May 24 at 8:30 a.m. EDT. CFO Richard Pulik will participate in a fireside chat. Jefferies Healthcare Conference in New York City on Wednesday, June... Read More

ARU-1801 reduced vaso-occlusive events and days in the hospital for patients with severe sickle cell disease Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that data demonstrating the clinical benefit of the company's lead product candidate ARU-1801 for severe sickle cell disease (SCD) will be presented today in an oral presentation at the American Society of... Read More

Dr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s preclinical and clinical portfolio In addition to internal pipeline programs, Roivant companies Proteovant Therapeutics and VantAI have formed external drug development partnerships with leading companies to further innovate in... Read More

VantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets VantAI , an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally “undruggable” targets. The... Read More

VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’). The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, VantAI and Janssen will leverage VantAI's geometric deep learning platform to potentially generate... Read More

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis Tapinarof was well-tolerated in sensitive skin and intertriginous areas with majority of patients experiencing no irritation for up to 52 weeks Tapinarof was well tolerated with long term use and demonstrated continued and durable improvement in quality of... Read More

Roivant Social Ventures , a nonprofit philanthropic social impact organization launched by Roivant Sciences, today announced a major collaboration with Sanford Burnham Prebys, San Diego’s prestigious medical discovery institute. The groundbreaking initiative is designed to eliminate barriers to opportunity in the biopharma industry and expand inclusive access to healthcare. The initiative directly addresses three historic... Read More

Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET. A live webcast will be available under “Events & Presentations” on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events . About Roivant Sciences Roivant's mission is to improve the delivery of healthcare... Read More

Roivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential first-in-class small molecule modulator of splicing factor 3B subunit 1 (SF3B1) for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes Dermavant has hired key commercial leadership positions in... Read More

Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ET Roivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and... Read More

Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ET SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of the Roivant... Read More

Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes Roivant JPM presentation scheduled for Monday, January 10, at 2:15 p.m. ET Roivant Sciences (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has entered into a licensing agreement with Eisai Co.,... Read More

Nanome , the first virtual reality software company to launch an immersive real-time collaboration platform for scientific discovery, today announced that the company has executed its largest deployment to date with Roivant Discovery , the drug discovery engine for Roivant Sciences (Nasdaq: ROIV). Roivant, a biopharmaceutical company based in Boston, New York and Basel now uses Nanome to gain deeper insights from their... Read More

Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion. Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients with plaque psoriasis (n=763). The study demonstrated 58% of patients who entered the study with a PGA score ≥2 achieved a PGA score of 0 or 1 and long-term use of tapinarof provided improved and durable effects for up to 52... Read More

Quarterly investor call and webcast scheduled on Monday, November 15 th at 8:00am ET Roivant will also present at the Jefferies London Healthcare and Evercore ISI HealthCONx investor conferences in November Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday,... Read More

Roivant Discovery , the drug discovery engine for Roivant Sciences (Nasdaq: ROIV), today announced that Dr. Gregory R. Bowman, Dr. Alex Dickson and Dr. Paul Robustelli have been appointed as 2021 Open Science Fellows. The Roivant Discovery Open Science Fellows program integrates cutting-edge research from leading academicians with the advanced computational physics research at Roivant Discovery. These three researchers were... Read More